XPH - Bristol-Myers Squibb: Massive Discount Spells Opportunity

2024-02-04 08:05:00 ET

Summary

• Bristol-Myers Squibb has faced revenue stagnation and a decline in stock price, but recent Q4 results suggest a potential rebound in top-line growth.
• BMY's in-line and new product portfolio showed strong sales growth, driven by top drugs like Eliquis and Opdivo.
• Despite risks like drug price reform and patent cliffs, BMY's strong balance sheet, attractive valuation, and high dividend yield compared to historical levels make it a compelling opportunity at present.

I'm admittedly a proponent of investing in stocks, considering that it creates a viable path to wealth accumulation by everyday retail investors. This is especially considering market innovations that include brokerage firms offering free trading thanks to industry disrupter Robinhood ( HOOD ), which is a nice bonus that didn't exist a generation ago....

For further details see: